Indo Borax Q1 FY27: Revenue Up 31% to ₹70.36 Cr, Net Profit Up 59% to ₹16.25 Cr
Indo Borax reported Q1 FY27 operating revenue of ₹70.36 crore, up 31.34% YoY. Net profit increased by 59.31% to ₹16.25 crore. The company is acquiring Kronox Lab Sciences and plans ₹50 crore Capex for Boron oxide and Boric acid expansion over 2-3 years. Full-year revenue is projected at ₹250-260 crore with a 20% EBITDA margin.
The significant financial growth, coupled with a major acquisition and planned capital expenditures, are material events that will likely have a substantial impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue and net profit, along with improved margins. Strategic acquisitions and planned capacity expansions indicate a positive outlook for future growth.
Indo Borax & Chemicals Limited announced its financial results for the first quarter of FY2027, reporting a significant increase in both revenue and net profit. Operating revenue for the quarter ended June 30, 2026, stood at ₹70.36 crore, marking a 31.34% growth compared to ₹53.57 crore in the same period last year.
The company's EBITDA for the quarter surged by 62.16% to ₹19.8 crore, with an improved EBITDA margin of 28.1%. Net profit saw a substantial rise of 59.31%, reaching ₹16.25 crore from ₹10.2 crore in Q1 FY2026. The Earnings Per Share (EPS) for the quarter was ₹5.07. This strong performance was attributed to robust execution, enhanced capacity utilization, and higher product realizations amidst steady domestic orders.
In recent strategic moves, the Board of Directors approved the amalgamation of its wholly-owned subsidiary, Indo Borax Infrastructure Private Limited, with the parent company in July. Furthermore, in August, the company approved the acquisition of 64.26% equity in the listed specialty chemical player, Kronox Lab Sciences. The company also plans capital expenditure of approximately ₹50 crore over the next two to three years, primarily for expanding Boron oxide and Boric acid capacities. The acquisition of Kronox Lab Sciences involves a Capex plan of around ₹110 crore, with ₹80 crore already available in cash on Kronox's balance sheet, and further phases to be funded through internal accruals and operational cash flows.
The company anticipates closing FY2027 with revenues between ₹250 crore and ₹260 crore, maintaining an EBITDA margin of around 20%. Future growth is expected from capacity expansions in Boron oxide and Boric acid, along with leveraging the global presence and product portfolio of Kronox Lab Sciences.
What to do with a filing like this
Indo Borax & Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo Borax & Chemicals Limited. Read the original for the full detail.